Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Investors frequently juxtapose the reliable income streams of established pharmaceutical behemoths against the tantalizing upside potential of specialized biotech firms. In comparison of Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX), the decision hinges on balancing broad reach with niche expertise. Operating as a global pharmaceutical colossus, Amgen boasts a vast portfolio spanning multiple therapeutic domains.
Meanwhile, Vertex concentrates on groundbreaking treatments for rare ailments, previously commanding the cystic fibrosis market. The choice between these entities boils down to weighing a diversified income-generating powerhouse versus a specialized biotech with an expanding pipeline of prospects. Amgen's operations encompass the discovery and development of medicines aimed at combating serious conditions in oncology, inflammation, and rare diseases sectors.
The company's products are distributed worldwide, with a heavy reliance on key distributors McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH), which collectively accounted for about 77% of total global gross revenues in 2025, indicating a notable risk of customer concentration.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
